Related Experiment Video

Updated: Aug 18, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Cytotoxic T-lymphocyte antigen 4 gene polymorphisms in sarcoidosis patients

Noriko Hattori1, Takashi Niimi, Shigeki Sato

  • 1Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG
|May 11, 2005
PubMed
Abstract

Insights

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene variations do not increase sarcoidosis risk. However, specific CTLA-4 polymorphisms are linked to sarcoidosis severity, including ocular involvement and multi-organ disease.

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Ophthalmology

Background:

  • Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a key regulator of T-cell activation, crucial in immune responses.
  • Sarcoidosis is a systemic inflammatory disease with abnormal T-cell regulation.
  • CTLA-4 gene polymorphisms are implicated in various diseases, prompting investigation into their role in sarcoidosis.

Purpose of the Study:

  • To investigate the association between CTLA-4 gene polymorphisms (promoter -318 C/T and exon 1 +49 A/G) and sarcoidosis.
  • To determine if these genetic variations influence disease susceptibility or clinical manifestations.

Main Methods:

  • Genotyping of CTLA-4 promoter -318(C/T) and exon 1 +49(A/G) polymorphisms using polymerase chain reaction and direct genomic sequencing.
  • Comparison of genotype frequencies between 106 sarcoidosis patients and 100 healthy controls.
  • Analysis of genotype distribution in relation to clinical phenotypes, such as ocular involvement and number of affected organs.

Main Results:

  • No significant difference in CTLA-4 genotype distribution was observed between sarcoidosis patients and healthy controls.
  • Specific CTLA-4 genotypes (-318 CC and +49 AG/GG) were more frequent in sarcoidosis patients with ocular involvement.
  • The +49 GG genotype was associated with a higher number of affected organs in sarcoidosis patients.

Conclusions:

  • CTLA-4 polymorphisms are not associated with susceptibility to sarcoidosis.
  • These genetic variations significantly impact sarcoidosis phenotypes, particularly ocular involvement and disease extent.
  • Further research may elucidate the mechanisms by which CTLA-4 variants influence sarcoidosis clinical presentation.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...